This comes together at exactly the point in time that PGC completes it's Immunolab expansion.
John Walstab is experienced in the Asian Market.
PGC has long ben pushin to get into the Aian market this will give them clout. The merged company will give PGC better exposure to the Australian hospital sector.
CH2 is well liked in the Hospital sector but has NO access to Asian markets at present.
End result is that both companies get access to very much larher markets and therefore growth potential.
Makes sense to me.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $645.5M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $23.76K | 61.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26000 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 11500 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PGC (ASX) Chart |